M2 Macrophage-Derived Small Extracellular Vesicles Ameliorate Pyroptosis and Intervertebral Disc Degeneration

Area of Science:

• Biomedical Engineering
• Regenerative Medicine
• Cell Biology

Background:

• Intervertebral disc degeneration (IDD) is a significant clinical challenge with limited regenerative capacity.
• Current therapeutic strategies for IDD are often unsatisfactory, necessitating novel approaches.
• Small extracellular vesicles (sEVs) from M2 macrophages (M2-sEVs) have shown anti-inflammatory properties and potential for tissue repair.

Purpose of the Study:

• To investigate the therapeutic potential and underlying mechanisms of M2-sEVs in intervertebral disc regeneration.
• To explore the role of M2-sEVs in regulating nucleus pulposus cell (NPC) behavior and pyroptosis.
• To develop a sustained-release delivery system for M2-sEVs to enhance their efficacy in IDD models.

Main Methods:

• In vitro studies on nucleus pulposus cells (NPCs) treated with M2-sEVs.
• Bioinformatic analysis and experimental validation of microRNA (miR) expression, specifically miR-221-3p.
• Fabrication of a decellularized extracellular matrix hydrogel (dECM) for controlled M2-sEVs release.
• In vivo evaluation of dECM/M2-sEVs in an intervertebral disc degeneration (IDD) animal model.

Main Results:

• M2-sEVs inhibited NPC pyroptosis, enhanced cellular viability, and promoted NPC migration in vitro.
• miR-221-3p was identified as a key molecule transferred by M2-sEVs, suppressing PTEN and NLRP3 expression.
• The dECM/M2-sEVs hydrogel demonstrated biocompatibility and controlled release, effectively delaying IDD progression in vivo.

Conclusions:

• M2-sEVs represent a promising cell-free therapeutic strategy for intervertebral disc regeneration.
• The mechanism involves M2-sEVs-mediated transfer of miR-221-3p, inhibiting pyroptosis pathways in NPCs.
• A dECM-hydrogel delivery system enhances the therapeutic efficacy of M2-sEVs for treating IDD.